Smithkline Beecham Corporation

Glaxo Group Limited

Steven James Stanway

Colin Andrew Leach

Stephen Allan Smith

Robert John Ife

Deirdre Mary Bernadette Hickey

Ivan Leo Pinto

David Timothy Macpherson

Christopher Norbert Johnson

Andrew Kenneth Takle

Aaron Bayne Miller

Peter Henry Milner

Andrew Faller

Giancarlo Trani

Xi Liang

David G Jones

Alan Naylor

Mervyn Thompson

Geoffrey Stemp

John Liddle

Emmanuel Hubert Demont

Susan Marie Westaway

David Robert Vesey

Daryl Simon Walter

Antoinette Naylor

Mark Patrick Healy

Susan Roomans

Martin Edward Swarbrick

Alessandra Gaiba

Antoinette Wilson

Sally Redshaw

Leontine Saskia Trouw

Keith James Millan Moore

Deirdre Mary B Hickey

Stephen Allen Smith

Pyrimidone compounds of formula (I): are inhibitors of the enzyme Lp-PLAand are of use in treating atherosclerosis.

Compounds

The present invention relates to novel benzylpiperazine derivatives such as compounds of formula (I), which have activity as agonists of the GPR38 receptor and the use of such compounds or pharmaceutical compositions thereof in the treatment of gastrointestinal disorders. 

Benzylpiperazine derivatives and their medical use

A compound of formula (I) or a pharmaceutically acceptable derivative thereof, wherein, R, R, R, R, R, m, n and X are as defined in the specification; a process for preparing such compounds; a pharmaceutical composition comprising such compounds; and the use of such compounds in medicine.

[object Object]

The present invention relates to novel indazole derivatives having pharmacological activity, processes for their preparation, compositions containing them and uses of these compounds in the treatment of estrogen receptor beta mediated diseases.

Indazoles used to treat estrogen receptor beta mediated disorders

The present invention relates to novel indole derivatives having pharmacological activity, processes for their preparation, compositions containing them and the use of these compounds in the treatment of estrogen receptor beta mediated diseases.

5,6-trimethylenepyrimidin-4-one compounds

Pyrimidone compounds of formula (I): are inhibitors of the enzyme Lp-PLAand are of use in treating atheroscelerosis.

Pyrimidine compounds

The present invention relates to novel hydroxyethylamine compounds having Asp2 (&#x3b2;-secretase, BACE1 or Memapsin) inhibitory activity, processes for their preparation, to compositions containing them and to their use in the treatment of diseases characterised by elevated &#x3b2;-amyloid levels or &#x3b2;-amyloid deposits, particularly Alzheimer's disease.

Hydroxyethylamine derivatives for the treatment of Alzheimer's disease

Compounds of formula (I): are inhibitors of the enzyme Lp-PLAand are of use in therapy, in particular for treating atherosclerosis.

Pyridinone derivatives for treatment of atherosclerosis

5,6 -Trimethylenepyrimidin-4-one compounds

The present invention relates to novel hydroxyethylene compounds having Asp2 (&#x3b2;-secretase, BACE1 or Memapsin) inhibitory activity, processes for their preparation, to compositions containing them and to their use in the treatment of diseases characterised by elevated &#x3b2;-amyloid levels or &#x3b2;-amyloid deposits, particularly Alzheimer's disease.

Benzamide derivatives, processes for their preparation, and their pharmaceutical use

This invention relates to novel compounds that can complex with lanthanide cations, processes for their preparation and the use of the resulting lanthanide chelates as biomolecular probes.

Cinoxacin lanthanide chelates and their use as biomolecular probes

Growing community of inventors

Harlow, United Kingdom

Steven James Stanway